GT Biopharma Inc. (GTBP) Attends 31st Annual ROTH Conference
GT Biopharma (OTCQB: GTBP) is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based off its proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms. GT’s TriKE and TetraKE platforms generate proprietary moieties designed to harness and enhance the cancer killing abilities of a patient's own natural killer, or NK, cells. Once bound to a NK cell, the moieties are designed to enhance the NK cell and precisely direct it to one or more specifically targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately…







